Development of leprosy and type 1 leprosy reactions after treatment with infliximab: a report of 2 cases.
Humanized monoclonal antibodies to tumor necrosis factor- alpha are valuable for the treatment of rheumatologic conditions, but they have been associated with the development of serious infections. We report the first 2 cases of leprosy developing after treatment with infliximab. After discontinuation of infliximab, both patients developed type 1 ("reversal") leprosy reactions.
Scollard
D M
DM
National Hansen's Disease Programs, Louisiana State University, Baton Rouge, LA 70803, USA. dscoll1@lsu.edu
Joyce
M P
MP
Gillis
T P
TP
D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000276:immunology / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000276:immunology / Q000627:therapeutic use; D001168:Arthritis / Q000188:drug therapy*; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D000069285:Infliximab; D007917:Leprostatic Agents / Q000627:therapeutic use; D015439:Leprosy, Borderline / Q000139:chemically induced / Q000209:etiology* / Q000382:microbiology; D008297:Male; D008875:Middle Aged; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D005938:Glucocorticoids; D007917:Leprostatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab